SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

Cara Therapeutics Q1 EPS $(0.620), Inline, Sales $8.093M Beat $4.760M Estimate

Cara Therapeutics (NASDAQ:CARA) reported quarterly losses of $(0.620) per share which met the analyst consensus estimate. This is a 10.71 percent decrease over losses of $(0.560) per share from the same period last year.

Benzinga · 05/11/2020 20:06

Cara Therapeutics (NASDAQ:CARA) reported quarterly losses of $(0.620) per share which met the analyst consensus estimate. This is a 10.71 percent decrease over losses of $(0.560) per share from the same period last year. The company reported quarterly sales of $8.093 million which beat the analyst consensus estimate of $4.760 million by 70.02 percent. This is a 84.69 percent increase over sales of $4.382 million the same period last year.